Lama laba combination copd12/30/2023 Our results suggest that treating patients with COPD with UMEC/VI might improve their lung function and quality of life more than alternative bronchodilators. All the medicines we compared had similar side effects. Patients treated with UMEC/VI had better quality of life than those receiving some other treatments, but not all. We found that patients treated with UMEC/VI had better lung function than patients treated with alternative LAMA/LABA combinations or bronchodilators used on their own. We analysed data from 49 clinical trials that met these criteria. We systematically searched for evidence from clinical trials in adult patients with COPD that were at least 8 weeks long and that compared LAMA/LABA combinations with a LAMA, a LABA, or another LAMA/LABA combination. Network meta-analysis is a way of comparing two or more medicines by analysing data from many studies. In this study, we used network meta-analysis to compare a LAMA/LABA combination medicine called umeclidinium and vilanterol (UMEC/VI) with other LAMAs and LABAs used alone or in combination to treat patients with COPD. Only a few clinical trials have compared different LAMA/LABA combinations with each other, so it is unclear which LAMA/LABA combination provides the greatest benefits for patients. There are two different types of bronchodilators, namely long-acting muscarinic antagonists (LAMAs) and long-acting β 2-agonists (LABAs), which can be used on their own or combined (LAMA/LABAs). Bronchodilators are medicines that open the airways, allowing patients with chronic obstructive pulmonary disease (COPD) to breathe more easily.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |